Biotech Vendor Services, Inc.

www.bvsweb.com

BVS provides effective and cost-saving vendor management services to Life Sciences companies and institutes. We help drug delivery, clinical, manufacturing, and R&D departments of all sizes manage their suppliers by setting up customized vendor product

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

RECIPHARM AND MODERNA FINALIZE AGREEMENT TO SUPPORT FORMULATION AND FILL-FINISH A PART OF THE MODERNA COVID-19 VACCINE SUPPLY OUTSIDE OF THE U.S.

Recipharm | January 04, 2021

news image

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the imm...

Read More

ALLIGATOR BIOSCIENCE PRESENTS POSITIVE BIOMARKER DATA DEMONSTRATING PROOF OF MECHANISM IN MITAZALIMAB CLINICAL PHASE I STUDY

PR Newswir | September 04, 2020

news image

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020."The presented biomarker data confirm the proof of mechanism and strengt...

Read More

Industrial Impact

PICTOR ANNOUNCES FUNDING ROUND AFTER SUCCESSFUL LAUNCH IN NEW ZEALAND AND USA OF SARS-COV-2 ANTIBODY TEST

Pictor | December 05, 2022

news image

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in det...

Read More

Industrial Impact, Medical

LABCENTRAL IGNITE LAUNCHES IGNITEVC TO ACCELERATE DIVERSITY AND INCLUSION IN LIFE SCIENCES VENTURE CAPITAL AND INNOVATOR COMPANIES

Prnewswire | April 27, 2023

news image

LabCentral Ignite, a platform dedicated to advancing racial, gender and other representation and opportunity within the life sciences field, today launched IgniteVC in partnership with the Bioscience & Investor Inclusion Group (BIIG). BIIG is a grassroots effort driven by leaders from venture capital (VC) firms and startups. The new initiative aims to cultivate a highly inclusive life sciences venture capital community and support the growth of more diverse and inclusive portfolio comp...

Read More
news image

Medical

RECIPHARM AND MODERNA FINALIZE AGREEMENT TO SUPPORT FORMULATION AND FILL-FINISH A PART OF THE MODERNA COVID-19 VACCINE SUPPLY OUTSIDE OF THE U.S.

Recipharm | January 04, 2021

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the imm...

Read More
news image

ALLIGATOR BIOSCIENCE PRESENTS POSITIVE BIOMARKER DATA DEMONSTRATING PROOF OF MECHANISM IN MITAZALIMAB CLINICAL PHASE I STUDY

PR Newswir | September 04, 2020

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020."The presented biomarker data confirm the proof of mechanism and strengt...

Read More
news image

Industrial Impact

PICTOR ANNOUNCES FUNDING ROUND AFTER SUCCESSFUL LAUNCH IN NEW ZEALAND AND USA OF SARS-COV-2 ANTIBODY TEST

Pictor | December 05, 2022

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in det...

Read More
news image

Industrial Impact, Medical

LABCENTRAL IGNITE LAUNCHES IGNITEVC TO ACCELERATE DIVERSITY AND INCLUSION IN LIFE SCIENCES VENTURE CAPITAL AND INNOVATOR COMPANIES

Prnewswire | April 27, 2023

LabCentral Ignite, a platform dedicated to advancing racial, gender and other representation and opportunity within the life sciences field, today launched IgniteVC in partnership with the Bioscience & Investor Inclusion Group (BIIG). BIIG is a grassroots effort driven by leaders from venture capital (VC) firms and startups. The new initiative aims to cultivate a highly inclusive life sciences venture capital community and support the growth of more diverse and inclusive portfolio comp...

Read More